# illumax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/illumax

- Industry: Medical Devices & Equipment
- Headquarters: Chengdu, China
- Website: www.illumaxbio.com
- Latest round: Series A (May 8, 2023)
- Investors on record: 4

## About

Based in Chengdu, China, and founded in 2018, illumax operates as a provider of clinical immune and molecular diagnostic systems, specializing in the development of single-component luminescent flow-through platforms. The company has an industrial base of nearly 4,000 square meters in Chengdu International Medical City. The main products have been awarded NMPA certification and European CE certification. The company's fully automated POCT chemiluminescence is certified in 2020. In May 2023, illumax completed a series A funding led by Sichuan Development Industry Led Equity Investment Fund Management, with participation from other new investors Geuniom Group and Sichuan Venture Capital, and returning investor CD Capital and other individual investors.

The company specializes in the development and manufacture of single-component chemiluminescence, single-component flow-through fluorescence and laboratory automation products, and provides an open ecological platform for chemiluminescence and flow-through fluorescence. The company's main products are the fully automated flow-through fluorescence immunoassay P16, the single-component chemiluminescence immunoassay lumilite8 and the fully automated chemiluminescence immunoassay lumiflx16. The products can be used in scenarios such as laboratory departments, ICUs, emergency departments, cardiology departments, chest pain centers, emergency vehicles and clinics at all levels of healthcare.

## Funding rounds

- Series A, May 8, 2023 — CD Capital, Sichuan Venture Capital, Sichuan Development Industry Led Equity Investment Fund Management, Geuniom Group
- Angel, Jul 22, 2021 — CD Capital

## Investors

- CD Capital — Angel, Series A
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series A
- Sichuan Development Industry Led Equity Investment Fund Management — Series A
- Geuniom Group — Series A